F-Prime Capital is one of the few large global VC firms that has built over 30 companies from scratch rather than just backing existing startups, drawing on Fidelity's resources to combine deep healthcare and technology expertise with a structured company-formation engine that pulls together academic founders across multiple geographies. The firm operates with sister fund Eight Roads to create one of the broadest cross-border VC footprints, systematically syndicating ideas across the U.S., Europe, China, Japan, India, and Israel while maintaining a distinctive "technical-risk-yes, regulatory-risk-no" filter that avoids heavy regulatory categories like broad antibiotics in favor of rare diseases and gene therapy where FDA pathways are clearer.